Dr. Urszula Sobol, MD
Claim this profileIllinois Cancer Specialists
Studies Ovarian Cancer
Studies Ovarian Tumors
7 reported clinical trials
15 drugs studied
Area of expertise
1Ovarian Cancer
Stage III
Stage IV
FRα positive
2Ovarian Tumors
Stage III
Stage IV
FRα positive
Affiliated Hospitals
Clinical Trials Urszula Sobol, MD is currently running
Selinexor Maintenance Therapy
for Endometrial Cancer
The purpose of this study is to evaluate the efficacy and safety of selinexor as a maintenance treatment in patients with p53 wt endometrial carcinoma (EC), who have achieved a partial response (PR) or complete response (CR) (per Response Evaluation Criteria in Solid Tumors version 1.1 \[RECIST v 1.1\]) after completing at least 12 weeks of platinum-based therapy. A total of 220 participants will be enrolled in the study and randomized in a 1:1 ratio to maintenance therapy with either selinexor or placebo.
Recruiting1 award Phase 32 criteria
T-DM1 + Tucatinib
for Breast Cancer
This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving T-DM1 and tucatinib may work better in preventing breast cancer from relapsing in patients with HER2 positive breast cancer compared to T-DM1 alone.
Recruiting1 award Phase 313 criteria
More about Urszula Sobol, MD
Clinical Trial Related4 years of experience running clinical trials · Led 7 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Urszula Sobol, MD has experience with
- Paclitaxel
- Carboplatin
- Tucatinib
- Oregovomab
- Trilaciclib
- Gemcitabine
Breakdown of trials Urszula Sobol, MD has run
Ovarian Cancer
Ovarian Tumors
Cancer
Breast Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Urszula Sobol, MD specialize in?
Urszula Sobol, MD focuses on Ovarian Cancer and Ovarian Tumors. In particular, much of their work with Ovarian Cancer has involved Stage III patients, or patients who are Stage IV.
Is Urszula Sobol, MD currently recruiting for clinical trials?
Yes, Urszula Sobol, MD is currently recruiting for 2 clinical trials in Arlington Heights Illinois. If you're interested in participating, you should apply.
Are there any treatments that Urszula Sobol, MD has studied deeply?
Yes, Urszula Sobol, MD has studied treatments such as Paclitaxel, Carboplatin, Tucatinib.
What is the best way to schedule an appointment with Urszula Sobol, MD?
Apply for one of the trials that Urszula Sobol, MD is conducting.
What is the office address of Urszula Sobol, MD?
The office of Urszula Sobol, MD is located at: Illinois Cancer Specialists, Arlington Heights, Illinois 60005 United States. This is the address for their practice at the Illinois Cancer Specialists.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.